A clear-eyed look at the psilocybin clinical trial landscape — what studies have been done, what they found, and what researchers say remains unknown.
Psilocybin research has accelerated dramatically since 2006, when a Johns Hopkins team demonstrated that a single high-dose session produced lasting positive personality changes in healthy volunteers. As of 2024, over 100 registered clinical trials are exploring psilocybin's therapeutic potential across depression, addiction, end-of-life anxiety, OCD, eating disorders, and PTSD. This article summarizes what the research has found, where the regulatory landscape stands, and what researchers consistently say they do not yet know.
Griffiths et al. 2016 (Johns Hopkins)
The landmark study by Roland Griffiths and colleagues — published in Journal of Psychopharmacology — enrolled 51 adults with life-threatening cancer diagnoses and clinically significant depression or anxiety. Participants were rigorously screened: those with a personal or family history of psychotic or bipolar disorders were excluded, as were individuals taking MAOIs, SSRIs, or benzodiazepines. The study used a crossover design: participants received both a high dose of synthetic psilocybin (30mg/70kg) and an active placebo (a very low dose of psilocybin, 1–3mg/70kg) in two sessions months apart, with careful blinding procedures.
Findings were striking. A single high-dose session produced substantial and sustained decreases in depression and anxiety. At 6-month follow-up, approximately 78% of participants showed clinically significant reductions in depression and 83% in anxiety. Approximately 67% of participants met criteria for complete remission on at least one measure at the 6-month mark. Eighty percent rated the experience among the five most personally meaningful of their lives; 67% rated it among the five most spiritually significant experiences they had ever had.
Researchers used the Mystical Experience Questionnaire (MEQ30) to assess the depth and completeness of the mystical-type experience during the session. This turned out to matter: the intensity of mystical experience — not just having taken a large dose — correlated with therapeutic outcome. Participants who reported more complete mystical experiences tended to show greater symptom improvement at follow-up. This finding has been replicated in subsequent trials and has shaped how researchers think about mechanism.
Carhart-Harris et al. 2021 (New England Journal of Medicine)
In 2021, Robin Carhart-Harris and colleagues at Imperial College London published the largest head-to-head comparison of psilocybin against an established antidepressant. The New England Journal of Medicine paper enrolled 59 adults with moderate-to-severe major depressive disorder. The trial excluded treatment-resistant cases — that population was the subject of a separate ongoing programme — and excluded participants with a history of psychosis, mania, or active suicidality.
Half the participants received two doses of 25mg psilocybin, three weeks apart, with psychological support before, during, and after each session. The other half received a six-week course of escitalopram — a selective serotonin reuptake inhibitor (SSRI) commonly sold as Lexapro, and among the most widely prescribed antidepressants in the world. The placebo arm's psilocybin doses were very low (1mg per session) to preserve blinding.
The primary outcome was the Quick Inventory of Depressive Symptomatology (QIDS-SR-16), a 16-item self-report instrument that asks patients to rate symptom severity over the preceding seven days. At 6 weeks, the psilocybin group showed a mean QIDS reduction of 8.0 points; the escitalopram group showed 6.0 points. The difference was not statistically significant (p = 0.17). The trial was not powered to establish equivalence or non-inferiority — it was explicitly designed as proof-of-concept. However, on most secondary measures — wellbeing, meaning, connectedness, work and social functioning — psilocybin outperformed escitalopram, and several of these differences were statistically significant. Remission rates were 57% for psilocybin and 28% for escitalopram, though again the trial was not powered to establish a reliable difference. The authors were appropriately careful: this is one small trial, not a basis for replacing standard care.
Imperial College: Treatment-Resistant Depression
A separate programme at Imperial has focused on patients for whom at least two full antidepressant courses have failed — meeting the standard clinical definition of treatment-resistant depression (TRD). Published across several papers in Psychopharmacology, Scientific Reports, and JAMA Psychiatry, these open-label studies enrolled patients who had failed 2–8 prior antidepressant trials. The protocol used two psilocybin sessions (10mg followed by 25mg, seven days apart) in combination with psychological support.
Results at one week showed response rates of approximately 67%. At three months the rate had declined to roughly 42%, which still represents clinically meaningful benefit in a population for whom conventional pharmacotherapy has repeatedly failed. The speed of effect — often apparent within 24 hours of the session — stands in sharp contrast to SSRIs, which require continuous dosing over 4 to 6 weeks to reach full therapeutic effect.
Addiction Research
Outside mood disorders, several trials deserve attention. A 2022 randomized controlled trial by Matthew Johnson and colleagues at Johns Hopkins — published in Nature Medicine — found that two psilocybin sessions combined with cognitive-behavioural therapy produced an 80% abstinence rate from tobacco at 6 months, compared to 28% in the CBT-only arm, with a 67% abstinence rate at 12-month follow-up. This is substantially higher than pharmaceutical smoking cessation aids (varenicline typically achieves 30–40% at 6 months).
A separate randomized trial published in JAMA Psychiatry documented significant reductions in heavy drinking in adults with alcohol use disorder following psilocybin-assisted therapy. The psilocybin group showed 48% reduction in heavy drinking days at 32 weeks, versus 30% in the placebo group — a difference that was statistically significant.
In 2018, the FDA granted Breakthrough Therapy designation to Compass Pathways' synthetic psilocybin (COMP360) for treatment-resistant depression. Breakthrough designation does not mean approval — it initiates more intensive FDA guidance to expedite development for conditions with serious unmet need. Compass subsequently ran a phase 2b randomized controlled trial across 22 sites in 10 countries (n=233), published in The Lancet in 2022. The 25mg dose arm showed a statistically significant reduction in depression severity scores versus placebo at three weeks (effect size −0.37 on the Montgomery-Åsberg Depression Rating Scale), with 29% of the 25mg group achieving remission at three weeks compared to 8% in the placebo group. Phase 3 planning is underway.
USONA Institute received a separate Breakthrough Therapy designation for synthetic psilocybin in major depressive disorder. Yale, UCSF, NYU, and University of Wisconsin-Madison are among the US institutions with active psilocybin trials. In Europe, King's College London and Leiden University are running registered trials. In Canada, University of Calgary and Université de Montréal have received approval to run clinical research.
The commercial pipeline also includes Filament Health (Canadian company working on naturally-derived psilocybin extracts) and several other drug development entities. This is a rapidly evolving area; trial registries are a more reliable source of current status than any single article.
Mechanism specificity
Is therapeutic benefit caused primarily by psilocybin's pharmacological action — its agonism at 5-HT2A serotonin receptors, which triggers downstream effects including reduced default mode network activity and increased neural entropy — or by the therapeutic support provided alongside it, or by expectancy effects, or by some interaction of all three? Unblinding is nearly impossible: participants nearly universally know whether they received the active compound. This means psychological expectancy and therapeutic attention cannot be fully separated from pharmacological effect. The correlation between mystical experience intensity and outcome is consistent with a model in which the phenomenological quality of the session matters, not just the pharmacology — but it doesn't prove it. Active placebo designs (using low-dose psilocybin) do not fully resolve the problem.
Long-term safety at scale
Most trials have involved carefully screened participants, extensive before-and-after support structures, and professional facilitation throughout. Real-world use — which already far exceeds clinical trial exposure in absolute numbers — happens without screening, without therapist support, without structured integration, and often at higher frequencies than any clinical protocol endorses. Data on long-term outcomes, repeated high-dose use, and use in unsupervised settings is almost entirely absent from the peer-reviewed literature. Health Canada, the FDA, and the EMA have each noted this gap in their regulatory communications.
Optimal protocols
Dose, number of sessions, session timing, therapist training requirements, and session structure vary substantially across trials. Johns Hopkins uses 30mg/70kg with a full preparation and integration framework and music during sessions. Compass Pathways trials use 25mg with "psychological support" — not structured psychotherapy. The Imperial trials have used 10mg followed by 25mg in sequential sessions. No protocol has been validated against another in a head-to-head comparison, and there is no scientific consensus on whether the psychotherapy component is essential, adjunctive, or separable from the pharmacological effect.
Contraindicated populations
All major trials exclude individuals with personal or family history of psychotic disorders, bipolar I, and most conditions involving manic episodes. Those with significant cardiovascular conditions, those taking MAOIs, SSRIs (in most protocols), lithium, or tramadol are also excluded. The effects of psilocybin in these populations are almost entirely unstudied. Given that several of these excluded conditions — bipolar disorder, treatment-resistant schizophrenia, psychosis-spectrum disorders — carry some of the highest psychiatric burden, the evidence gap is both a scientific and an ethical problem. The exclusion criteria are safety precautions, not confirmed contraindications; the evidence simply doesn't exist either way for most of them.
Psilocybin remains a Schedule III controlled substance in Canada under the Controlled Drugs and Substances Act (CDSA). There is no approved indication, and the compound is not available through standard prescription channels.
A legal pathway exists through Health Canada's Section 56 exemption process. Section 56 allows the Minister to exempt individuals or classes of individuals from certain CDSA restrictions where it is necessary for a medical purpose. As of 2020, this pathway was used to grant exemptions to a small number of terminally ill patients; by 2022, Health Canada had expanded access for healthcare providers to obtain psilocybin for training and treatment of patients with serious conditions under this exemption framework.
The Special Access Program (SAP) provides a second avenue: physicians can apply to Health Canada on behalf of individual patients with serious or life-threatening conditions who have not responded to available treatments. SAP requests are evaluated case by case and are not a general clinical access pathway.
Several Canadian academic institutions have received approval to conduct psilocybin trials. ClinicalTrials.gov lists registered Canadian studies, most of which are actively recruiting. Filament Health's work on naturally-derived psilocybin formulations is a Canadian example of the commercial development activity now underway.
The psilocybin research landscape is genuinely promising — particularly for treatment-resistant depression, end-of-life anxiety, and certain addiction presentations — but is still early-stage by the standards of pharmaceutical development. Most completed trials are small, limited to specific screened populations, and conducted under conditions that differ significantly from real-world use. Effect sizes are often large by psychiatric standards, but so is the therapeutic apparatus that surrounds the compound in every trial design.
Researchers at leading institutions have consistently emphasized that psilocybin in therapeutic contexts requires professional facilitation, appropriate screening, and structured preparation and integration. The compound is not positioned by its own researchers as a take-at-home treatment. The distance between what the research shows under controlled conditions and what it implies for recreational or self-directed use is one that the literature is careful to state — and that popular coverage frequently glosses over.
For deeper engagement with the primary literature, see the research citations in individual psilocybin catalogue entries, or explore the registries at ClinicalTrials.gov and the Multidisciplinary Association for Psychedelic Studies (MAPS) Clinical Research Bulletin.
About the author
D.Spora — Master Grower
Every article on shroomDOSAGE starts with primary sources — clinical trials, published assay data, peer-reviewed pharmacology. We translate the findings into plain English so you can understand what the science actually says, without needing a medical degree. Sources are cited inline. Nothing here constitutes medical advice.
Your cart is empty.
Browse the catalogue to add items.